Subscribe to Updates in Healthcare

RSS By Email

RSS By RSS

Add to Google Reader or Homepage

Subscribe in Bloglines


The Expertise Imperative and Compliance Technology
Access to a diverse array of specialized expert inputs drives superior decisions in every organizational context: within corporations, by investors and consultancies, and within nonprofits. When decision makers are confident of their decision inputs, they can respond more quickly and creatively to challenges and opportunities.Learn more about GLG's Compliance Framework


This page may include content provided by Council Members, your access to which is subject to the Terms of Use.
Find Out More

Donald Fleming, MD

Donald Fleming, MD, Division Head of Hematology and Oncology, Davis Health System, Inc.Division Head of Hematology and Oncology
Davis Health System, Inc.
Member of the Healthcare Council

Donald Fleming, MD, is the Head of Hematology-Oncology at the Medical Center of Vincennes. Previously, Dr. Fleming was a Tenured Professor in the Division of Hematology-Oncology at University of Louisville. He has published over 25 manuscripts in peer-reviewed journals and remains involved in clinical trials involving the treatment of hematologic and oncologic disorders. Dr. Fleming has also served as consultant for various pharmaceutical companies. (This is me - Update Profile)


Employment History
2008 - present Division Head of Hematology and Oncology
Davis Health System, Inc.
2002 - 2008 Division Head of Hematology and Oncology
Medical Center of Vincennes
1995 - 2002 Associate Professor of Oncology / Hematology
University of Louisville

GLG Study Groups with Donald Fleming, MD(?)

View All Study Groups with Donald Fleming, MD

GLG NewsSM Analyses by Donald Fleming, MD(?)

Opinions and analyses expressed in GLG News are solely those of the author. See the Terms of Use for details.
UK the model for US healthcare? | 08-14-2008
Analysis of: UK Says Kidney Cancer Drugs Are Too Pricey | www.pharmalot.com
Author: Donald Fleming, MD, Division Head of Hematology and Oncology, Davis Health System, Inc.

In this election year some have encouraged adoption of socialized medical services UK healthcare is an example of what some in this country have said we need to model our future healthcare system The recent use of biologics such as the TKIs have resulted in options for...

EGFR and Non Small Cell Lung Cancer ( NSCLCa) | 07-24-2008
Analysis of: Increased EGFR Gene Copy Number Detected by Fluorescent In Situ Hybridization Predicts Outcome in Non–Small-Cell Lung Cancer Patients Treated With Cetuximab and Chemotherapy | jco.ascopubs.org
Author: Donald Fleming, MD, Division Head of Hematology and Oncology, Davis Health System, Inc.

Recent BMS subanalysis indicate despite negative trial, EGFR indicates favorable outcome with platinum therapy EGFR will become target for frontline NSCLCa

Cancer Care Is getting out of reach | 07-10-2008
Analysis of: Costly Cancer Drug Offers Hope, but Also a Dilemma | www.nytimes.com
Author: Donald Fleming, MD, Division Head of Hematology and Oncology, Davis Health System, Inc.

The cost of medical care is increasing at an alarming rate The amount of money to support a physician's practice is going down at the same alarming rate especially in oncology

Erbitux and Lung cancer | 05-23-2008
Analysis of: Phase II trial of gemcitabine, docetaxel, and cetuximab in advanced non-small-cell lung cancer (NSCLC). | www.abstract.asco.org
Author: Donald Fleming, MD, Division Head of Hematology and Oncology, Davis Health System, Inc.

Erbitux has had a few high level trials in Non small lung cancer So far there does not appear to be a contributuion to chemotherapy Maybe we are going about it the wrong way

View All GLG News SM Analyses by Donald Fleming, MD

GLG InstituteSM Seminars with Donald Fleming, MD(?)

 
Donald Fleming, MD has not participated in any GLGi Seminars.
View all GLG InstituteSM Seminars in Healthcare

Request a project with Donald Fleming, MD









Note: GLG Experts do not provide personal medical advice, diagnosis or treatment through this site.

GLG's 750+ Clients Include:

40 of the leading 50
global mutual funds
15 of the leading 20
global banks
8 of the leading 10
private equity firms
90%+ client subscription renewal rate

Analytics


Generated at 2008-08-29T09:45:18.400